Boehringer Ingelheim has announced new data analyses from the pivotal Phase III TONADO 1&2 studies, which explored the efficacy and...
Boehringer Ingelheim presented the first data from the pivotal Phase III TONADO 1&2 studies (NCT01431274/NCT01431287) for the fixed-dose combination (FDC)...
Boehringer Ingelheim announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance...
The FDA approved a sNDA for Stiolto Respimat (olodaterol + tiotropium), from Boehringer, that adds data showing improvement in health-related...
Boehringer Ingelheim announced that the FDA approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray as a long-term, once-daily...
Boehringer Ingelheim has announced that the FDA accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC)...
Boehringer has submitted Marketing Authorisation Applications in 31 European countries for the once-daily, fixed-dose Respimat Soft Mist Inhaler (tiotropium +...
Tiotropium is a long-acting inhaled anticholinergic developed for the treatment of chronic obstructive pulmonary disease (COPD) and has been available since 2002.
The FDA has approved Spiriva Respimat (tiotropium bromide) inhalation spray, from Boehringer, for the long-term, once-daily maintenance treatment of bronchospasm...
Boehringer announced that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range...